論文 - 藤原 一男
-
Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.
Akaishi T, Takahashi T, Fujihara K, Abe M, Ishii T, Aoki M, Nakashima I, Misu T, Mugikura S.
PLoS One 3 ( 15(4) ) e0231225 2020年4月
-
MOG-IgG-associated disease.
Kaneko K, Takahahi T, Misu T, Nakashima I, Fujihara K.
Clin Exp Neuroimmunol 11 ( Suppl. 1 ) 28 - 33 2020年
-
Perivenous demyelination:association with anti-myelin oligodendrocyte glycoprotein.
Misu T, Takai Y, Takahashi T, Nakashima I, Fujihara K, Aoki M.
Clin Exp Neuroimmunol 11 ( Suppl. 1 ) 22 - 27 2020年
-
Trila of satralizumab in neuromyelitis optica spectrum disorder
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J
N Engl J 2019年11月
-
Long-term outcome of a group of Japanese children with myelin-oligodendrocyte glycoprotein encephalomyelitis without preventive immunosuppressive therapy
Hino-Fukuyo N, Haginoya K, Takahashi T, Nakashima I, Fujihara K, Takai Y, Akasaka M, Kure S
Brain Dev 2019年10月
-
Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behçet’s disease.
Fujimori J, Takahashi T, Matsumoto Y, Fujihara K, Takai Y, Misu T, Nakashima I
J Neuroimmunol 2019年6月
-
Neuromyelitis optica spectrum disorders: still evolving and broadening
Fujihara K
Curr Opin Neurol 2019年6月
-
【補体標的治療の現状と展望】視神経脊髄炎
黒田 宙、藤原 一男
BRAIN and NERVE: 神経研究の進歩 71 ( 6 ) 573 - 580 2019年6月
-
治療法の再整理とアップデートのために 専門家による私の治療 急性散在脳脊髄炎（ADEM）
松本勇貴, 藤原一男
日本医事新報 ( 4964 ) 42 - 42 2019年6月
-
Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders: tools for clinical practice and drug trial design
Palace J, Lin DY, Zeng D, Majed M, Elsone L, Hamid S, Messina S, Misu T, Sagen J, Whittam D, Takai Y, Leite MI, Weinshenker B, Cabre P, Jacob A, Nakashima I, Fujihara K, Pittock SJ
Brain 2019年5月
-
Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat.
Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, PeschL P, Bauer J, Takai T, Fujihara K, Nakashima I, Misu T, Reindl M, Lassmann H, Bradl M.
Acta Neuropathol 137 ( 3 ) 467 - 485 2019年3月
-
Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat
Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, PeschL P, Bauer J, Takai T, Fujihara K, Nakashima I, Misu T, Reindl M, Lassmann H, Bradl M
Acta Neuropathol 2019年3月
-
【視神経脊髄炎スペクトル障害（NMO-SD）】NMO-SDの疾患概念
三須 建郎、藤原 一男
脳神経内科 90 ( 1 ) 1 - 6 2019年1月
-
Debate on the treatment of multiple sclerosis: Experience from an intractable multiple sclerosis case with rebound syndrome after fingolimod cessation
Kuroda H, Nishiyama S, Matsumoto Y, Misu T, Fujihara K, Aoki M
Clin Exp Nuroimmunol 10 2019年
-
Trial of eculizumab in aquaporin-4 positive neuromyelitis optica spectrum disorder
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM
N Engl J Med 2019年
-
A randomised, placebo-controlled, double-blind trial of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: results of the N-MOmentum study
Cree B, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E
Lancet 2019年
-
NMO spectrum and MOG-antibody-related disseminated encephalomyelitis
Misu T, Fujihara K
Clin Exp Neuroimmunol 2019年
-
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.
Jurynczyk M, Jacob A, Fujihara K, Palace J.
Pract Neurol 2018年12月
-
脱髄性疾患
北山通朗, 藤原一男
研修医が知っておきたい神経疾患の診断と治療 11 ( 10 ) 56 - 67 2018年12月
-
視神経脊髄炎関連疾患と抗AQP4抗体 NMOSDの診断基準
松本勇貴, 藤原一男
Clinical Neuroscience,中枢神経系脱髄疾患-最前線抗MOG抗体の関与を考える 36 ( 11 ) 1306 - 1309 2018年11月